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EXTENDED ABSTRACT
A. Introduction
Congenital  Myasthenic  Syndromes  (CMS) conform  a
group  of  diverse  rare  diseases  characterized  by
neuromuscular  junction  (NMJ)  dysfunctions  resulting  in
muscle  weakness,  which  is  a  common  hallmark  in  these
conditions.  While  causative  genes  have  been  previously
described  ,  a  molecular  explanation  of  the  observed  large
range of phenotypic severity remains unclear.
In  this  work  we  undertook a  Personalized  Medicine
approach with the goal of elucidating the molecular processes
causing severity in CMS. Personalized Medicine is defined as
the  integration  of  molecular  research  with  clinical  data  in
order to deliver better diagnoses and treatments tailored to the
individual characteristics of each patient. 
We jointly analysed DNA and RNA from 20 samples from
an isolated region in Eastern Europe (Bulgaria),  integrating
RNA  sequencing  (RNAseq)  from  fibroblast  culture  and
Whole Genome Sequencing (WGS) from blood, identifying a
set of candidate genes. Since none of these genes’ features
(annotations, mutations, etc.) were able to explain severity ,
we  performed  a  multilayer  network  analysis  of  several
aspects  (interactome,  reactome  and  metabolome)  involving
the damaged genes of each CMS patient in our cohort.
B. Methods 
1 – RNAseq & WGS
Whole genome sequencing (WGS) data have been obtained
from  blood,  while  RNA  sequencing  (RNA-seq)  data  have
been  obtained  from  fibroblasts.  All  analyses  have  been
performed using RD-Connect project (https://rd-connect.eu/)
specific  pipeline  and  the  human  genome  GRCh37d5  as
reference. 
Copy Number Variants (CNVs) have been extracted using
ClinCNV (https://github.com/imgag/ClinCNV) by employing
a  set  of  Eastern  European  samples  as  background  control
group.  Heterozygous  compound  mutations  have  been
obtained by phasing the WGS and RNA-seq data, removing
variants  with  allele  frequency  >  3%,  outsde  exonic  and
splicing regions (Ensembl annotation), synonymous, and with
read depth (coverage) smaller than 8.
2 – Multilayer Community Detection
We generated a multilayer network using reactome [2], the
metabolome  [3],  and  the  interactome  [4]  layers.  The
multilayer community detection analysis was performed by
using MolTi software [5]. To study the relationship between
disease-associated  genes  multilayer  network  communities’
membership,  we  analyzed  the  curated  gene-disease
associations  of  the  DisGeNET  database
(http://www.disgenet.org/).
    C. Results
Albeit all affected individuals shared the very same causal
mutation   (a   deletion   within   the   acetylcholine    receptor
-AChR-  ε  subunit,  CHRNE  c.1327delG),  the  severity  of
symptoms across this cohort varies considerably regardless of
age  and  sex,  pointing  towards  causes  to  the  disease
phenotype  other  than  the  causal  variant.  In  this  work,  we
performed an in-depth characterization of 20 CMS samples
from patients from this cohort by analyzing multi-omics data
(see  Methods:  RNAseq  &  WGS).  Distinct  CMS  severity
levels have been classified by specialized physicians , namely
severe (8 patients) and not-severe (2 intermediate and 10 mild
patients)  disease  phenotypes.  In  particular,  the  clinical
phenotyping reports  the outcomes of  medical  tests such as
swallowing, speech,  respiratory dysfunction, as well  as  the
prescription of pharmacological treatments.
We jointly analyzed DNA and RNA from 20 patients, with
the  objective  of  validating  whether  the  severity  was
determined  by  the  accumulation  of  damaging  mutations
hampering the neuromuscular activity, on top of the CHRNE
damaging  mutation.  By  analysing  segregating  single
nucleotide  polymorphisms  (SNPs)  and  copy  number
variations (CNVs),  we could not find any unique cause of
severity.  Nevertheless,  we  observed  that  heterozygous
compound mutations are enriched in pathways related to the
extracellular matrix (ECM) receptor, which has been recently
proposed as a target  for  CMS therapy [1]. As a result,  we
used CNVs and heterozygous compound mutation gene sets
in the multilayer network analysis (Figure 1). 
Once  assessed  that  compound  heterozygous  variants  are
associated with functionally related pathways, we sought to
analyze  the  relationships  among  the  affected  genes  at
different  scales  .  We  generated  a  multilayer  network,  a
complex system representation in which distinct features of
nodes and edges are described by several layers, containing
different facets of molecular biology  (Figure 2), namely the
reactome [2], the metabolome [3], and the interactome [4].   
Fig. 1: Phenotypic severity spectrum and genomic work performed on the 
CMS cohort.
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We   performed  a  multilayer  community  analysis  using
MolTi,  a  software  that  adapts  classical  Louvain  clustering
analysis  into  multilayer  networks  [5]  and  looked  for
topological  relationships  between   the  affected  genes  and
previously known CMS causal genes [6].
We  identified  a  largest  component  module  of  damaged
genes  that  is  specific  of  the  severe  group  of  patients,
composed  of  15  genes  (Figure  2).  6  out  of  these  15  are
previously  described  CMS  causal  genes,  while  the  other
genes  are  mutated  with  damaging  compound heterozygous
mutations (9 out of 15, as agrin, a well-known CMS causal
gene present this type of mutations in one of the patients) or
CNVs (1 out of  15).  The mutated genes are involved in a
varied spectrum of functions at the neuromuscular junction,
such  as  neuromuscular  synapsis  development  and   AChR
clustering at the skeletal muscle fiber. Our results show that
alterations  in  proteoglycans  (AGRN,  HSPG2,  VCAN,
COL15A1),  tenascins  (TNC,  TNXB),  and  chromogranins
(CHGB)  are  specific  of  the  severe  group.  Strikingly,  no
proteoglycans  are  damaged  in  the  not-severe  group,
suggesting a direct involvement of ECM in CMS severity.
   D. Discussion
In this work, we tested the hypothesis that the severity of a
rare disease with a known causative mutation was determined
by  the  accumulation  of  additional  damaging  alterations
hampering  a  specific  impaired  functional  process.  In
particular,  we  performed  an  in-depth  analysis  of  20  CMS
patients,  from  a  narrow  and  geographically  isolated
population,  who  share  the  same  causative  mutation  in  the
acetylcholine  receptor  ε  subunit  (CHRNE),  presenting
different  levels  of  disease  severity,  as  assessed  by  expert
physicians.
Our results show that CMS severity can be ascribed to the
personalized impairment of specific classes and localizations
of  NMJ activities,  namely extracellular  matrix  components
(proteoglycans,  tenascins,  chromogranins)  and  postsynaptic
modulators of AChR clustering. Moreover, this work shows
that  coupling multilayer network analysis with personalized
omics information  helps give a molecular explanation of the
phenotypic severity of rare diseases.
Finally,  as  our results  suggest  that  severity  is  related  to
AChR clustering  at  the  AGRN-PLEC-LRP4-Laminins  axis
level,  severe affected patients may potentially benefit  from
pharmaceutical  interventions enhacing the AChR clustering
process. For example, beta-2 adrenergic receptor agonists like
ephedrine and salbutamol have been documented as capable
of enhancing AChR clustering and proved to be successful in
the treatment for severe AChR deficiency syndromes [7].
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Fig. 2: Multilayer network components, community analysis workflow and 
the identified largest component module of genes functionally related to 
neuromuscular junction function. 
In red, previously known CMS genes. In blue, genes mutated with 
compound heterozygous mutations. In white, genes mutated with copy 
number variants (CNVs).
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